Beryl Drugs vs Indoco Remedies: Fair Value & Quality
Both stocks run through our valuation models. Here is how Beryl Drugs (BERLDRG) and Indoco Remedies (INDOCO) compare, as of Aug 19, 2026.
As of Aug 19, 2026, Fair Value Calculator sees Beryl Drugs as the less overvalued of the two: Beryl Drugs trades at ₹23.00 versus a fair value of ₹12.89 (-44%), while Indoco Remedies trades at ₹221 versus ₹101 (-54%).
Beryl Drugs
BERLDRG.BSE · INR
-44%
upside to fair value
overvalued
Price₹23.00
Fair Value₹12.89
Quality55/100
Indoco Remedies
INDOCO.NSE · INR · Health Care
-54%
upside to fair value
overvalued
Price₹221
Fair Value₹101
Quality36/100
Get comparisons like this free by email every month: the most undervalued quality stocks.
Head-to-head numbers
Green value = the better side for that row (for valuation multiples: lower = cheaper).
Beryl DrugsIndoco Remedies
Valuation
27.4×P/E (TTM)—
0.57×P/S (TTM)0.01×
1.09×P/B—
4.3×EV/EBITDA3.6×
—Dividend yield0.1%
—Dividend per share₹0.20
Profitability
2%Net margin-5%
18%Operating margin4%
4%Return on equity-10%
4%Return on assets0%
Growth
29%Revenue growth (YoY)22%
-11.0%Avg. growth/yr (3Y)4.0%
6.3%Avg. growth/yr (5Y)8.7%
Balance & size
—Debt / equity0.55×
$1MMarket cap$236M
mixedGrowth qualityexpensive
Beryl Drugs leads: 5 to 4 metric wins.
Dash = not meaningfully computable, for example with negative equity.
Quality in detail
The quality score, broken down into the same factor families as on the stock page, 0 to 100 per family.
Beryl Drugsof which business quality 56 · market factors 46Indoco Remediesof which business quality 36 · market factors 43
ProfitabilityMargins and returns on capital today
55
21
Quality GrowthAre margins and returns improving?
40
57
CashflowEarnings quality: real cash, not paper profit
InvestmentDisciplined investing over empire-building
55
62
Low VolatilityCalm price path (market factor)
50
64
MomentumPrice trend over the last 3–12 months (market factor)
43
42
52W MomentumDistance to the 52-week high (market factor)
47
19
Net IssuanceBuybacks instead of dilution
82
68
What the models say
The median fair value (base case) per model family, each in the currency of its trading venue. Green = above the current price, red = below.
Beryl Drugs
Earnings-Based₹12.20
Multiples₹20.60
Asset-Based₹13.06
Economic Profit₹13.04
Growth Earnings₹12.89
9 of 12 models see the stock below the current price.
Indoco Remedies
Dividend Discount₹3.65
Multiples₹163
Asset-Based₹68.28
4 of 4 models see the stock below the current price.
Scenario ranges
From our cautious bear case to the optimistic bull case. The white tick is the current price: left of fair value means room to run.
Beryl Drugs
Bear ₹10.16Fair Value ₹12.89Bull ₹16.76
₹23.00 = current price (white tick)
Indoco Remedies
Bear ₹46.88Fair Value ₹101Bull ₹155
₹221 = current price (white tick)
Compare two other stocks
Tap a field and type again, ticker or company name.
Free, no sign-up
Ranked within their sector
Where each stock sits within its sector peer group. Band = middle 50% of peers, tick = median, dot = this stock.
Beryl Drugs
No peer data.
Indoco Remedies · Health Care
Quality score36 · bottom 25%
Fair value upside-54% · below median
Bottom line
As of Aug 19, 2026, Fair Value Calculator sees Beryl Drugs as the less overvalued of the two: Beryl Drugs trades at ₹23.00 versus a fair value of ₹12.89 (-44%), while Indoco Remedies trades at ₹221 versus ₹101 (-54%).
Beryl Drugs has the higher quality score (55/100).
Just your email for the monthly Top-25 report of the most undervalued quality stocks, with fair value, quality and price target. Plus 14 days of Pro to try, no card.
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click. Not financial advice.
A model-based valuation snapshot from 21 models. Values change with price and fundamentals; the date shown above applies.
